Actively Recruiting
Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
Led by First People's Hospital of Hangzhou · Updated on 2025-10-03
39
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
F
First People's Hospital of Hangzhou
Lead Sponsor
Z
Zhejiang University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to reveal the molecular characteristics and immune microenvironmental profile of signet ring cell carcinoma of the lung (LSRCC) in the Chinese population through integrated multi-omics analyses. The project plans to enroll formalin-fixed paraffin-embedded (FFPE) tissue samples and paired adjacent tissues from 39 patients with previously untreated LSRCC to establish a Chinese LSRCC molecular database. Whole-exome sequencing (WES) will be used to analyze gene mutations, such as single nucleotide variants (SNVs), copy number variants (CNVs), and fusion events. RNA-seq will be used to screen for differentially expressed genes (DEGs) and perform immunophenotyping, while multiplex immunohistochemistry will be employed to quantify the tumor immune microenvironment (TIME). The successful implementation of this project is expected to identify novel molecular biomarkers specific to the Chinese LSRCC population, enhance understanding of the unique immune phenotypes within this group, and-combined with clinical follow-up-establish correlations between molecular/immune signatures and therapeutic efficacy assessments, thereby providing evidence-based medical support for subsequent personalized precision diagnosis and treatment of LSRCC in this population.
CONDITIONS
Official Title
Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed, previously untreated LSRCC
- Adequate FFPE tumor tissue and paired adjacent non-tumor tissue available
- Expected survival of at least 12 weeks
- Patients or their legal guardians willing and able to provide written informed consent
- Availability of complete pathology and imaging data
You will not qualify if you...
- Prior systemic anticancer therapy
- Secondary LSRCC from a non-lung primary site
- Concurrent other malignancies
- Incomplete pathology results, missing imaging data, or unreliable follow-up information
- Pregnancy or lactation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine
Hangzhou, Zhejiang, China, 310006
Actively Recruiting
Research Team
S
Shirong Zhang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here